HealthQuill Oral medicine
Gilead Sciences and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer medicine to treat breast cancer and other solid tumours. 
Drugs Health Pharma

Gilead, Kymera Therapeutics in $750m pact to make new cancer drug

HQ Team June 25, 2025: Gilead Sciences Inc. and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer.

Read More
GSK Plc., a British global pharmaceutical company, announced the FDA had approved an oral drug to treat anaemia arising from chronic kidney disease in patients who have been on dialysis for four months.
Drugs Medical Pharma

GSK Plc gets FDA nod to make oral drug for anaemic CKD patients

GSK Plc., a British global pharmaceutical company, announced the FDA had approved an oral drug to treat anaemia arising from chronic kidney disease.

Read More